Answers are grounded in this paper and cite their sources.
The diagnostic value of the Aβ1-42/Aβ1-40 ratio in peripheral blood as a biomarker for Alzheimer’s disease (AD) remains a subject of considerable interest. However, this ratio in plasma exosomes is still underestimated. To investigate the potential clinical performances, this study has established a chemiluminescence immunoassay (CLIA) for the specific detection of Aβ1-42 and Aβ1-40 in plasma exosomes using single-chain variable fragments (scFv). Plasma samples from 20 AD patients and 20 non-AD individuals were detected by the established scFv-based CLIA, with the traditional monoclonal antibody (mAb)-based CLIA as the reference method. The results demonstrated that the plasma exosome Aβ1-42/Aβ1-40 ratio in AD patients (0.70 ± 0.35) was significantly lower than that in the non-AD control group (1.82 ± 0.79, p < 0.001). In comparison with the mAb-based assay, the scFv-based CLIA exhibited superior analytical performance, with a lower limit of detection (1 pg/mL vs. 50 pg/mL) and higher specificity (cross-reactivity rate < 5%). When the Aβ1-42/Aβ1-40 ratio of 1.075 was set as the cutoff value, the scFv-based assay achieved a diagnostic sensitivity of 90.0%, which was numerically higher than that of the mAb-based assay (85.0%), with comparable specificity (90.0% vs. 90.0%). Generally, this study has developed a highly sensitive and specific scFv-based method for the detection of plasma exosome Aβ subtypes, which supports that the plasma exosome Aβ1-42/Aβ1-40 ratio is a potential non-invasive biomarker for differentiating clinically diagnosed AD from non-AD controls in this pilot cohort.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: